Department of Emergency Internal Medicine, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui 233004, P.R. China.
Department of Pharmacology, Zhongshan School of Medicine, Sun Yat‑sen University, Guangzhou, Guangdong 510080, P.R. China.
Mol Med Rep. 2017 Sep;16(3):2814-2822. doi: 10.3892/mmr.2017.6920. Epub 2017 Jul 5.
Liver injury is a common pathological state in various types of liver disease; severe or persistent liver damage is the basis of hepatic failure. Ginsenoside Rg1 (Rg1), one of the primary active ingredients of ginseng, has been reported to reduce concanalin A‑induced hepatitis and protect against lipopolysaccharide‑ and galactosamine‑induced liver injury. However, the underlying protective mechanism of Rg1 in acute liver injury remains unclear. In the present study, a carbon tetrachloride (CCl4)‑induced acute liver injury model was established, and the protective effect of Rg1 on CCl4‑induced acute liver injury was demonstrated in cell culture and animal experimental systems. Further investigation of the mechanisms demonstrated that pretreatment with Rg1 reduced elevated levels of alanine aminotransferase and aspartate aminotransferase, enhanced the antioxidant activity of superoxide dismutase (SOD) and decreased malondialdehyde (MDA) content. Experiments in vitro demonstrated that Rg1 decreased p65 expression and inhibited nuclear factor (NF)‑κB activity. In addition to the effect of Rg1, an NF‑κB inhibitor promoted cell survival, enhanced SOD activity and reduced MDA level. It was observed through in vivo experiments that pretreatment with Rg1 inhibited NF‑κB expression and activity in Kupffer cells and reduced the serum levels of tumor necrosis factor‑α and interleukin‑6. In conclusion, the results of the present study indicated that pretreatment with Rg1 may rescue CCl4‑induced acute liver injury in vivo and in vitro through inhibition of NF‑κB activity, to restore the anti‑oxidative defense system and down‑regulate pro‑inflammatory signaling pathways. The present observations provide a theoretical foundation for the clinical application of Rg1 therapy in acute liver injury.
肝损伤是各种类型肝病的常见病理状态;严重或持续的肝损伤是肝衰竭的基础。人参的主要活性成分之一人参皂苷 Rg1(Rg1)已被报道可减轻钙通道阻滞剂 A 诱导的肝炎,并可预防脂多糖和半乳糖胺诱导的肝损伤。然而,Rg1 在急性肝损伤中的潜在保护机制尚不清楚。在本研究中,建立了四氯化碳(CCl4)诱导的急性肝损伤模型,在细胞培养和动物实验系统中证明了 Rg1 对 CCl4 诱导的急性肝损伤的保护作用。进一步的机制研究表明,Rg1 预处理可降低丙氨酸氨基转移酶和天冬氨酸氨基转移酶的升高水平,增强超氧化物歧化酶(SOD)的抗氧化活性并降低丙二醛(MDA)含量。体外实验表明,Rg1 降低了 p65 表达并抑制了核因子(NF)-κB 活性。除了 Rg1 的作用外,NF-κB 抑制剂还可促进细胞存活、增强 SOD 活性并降低 MDA 水平。体内实验观察到,Rg1 预处理可抑制库普弗细胞中 NF-κB 的表达和活性,并降低肿瘤坏死因子-α和白细胞介素-6 的血清水平。综上所述,本研究结果表明,Rg1 预处理可通过抑制 NF-κB 活性来挽救体内和体外 CCl4 诱导的急性肝损伤,恢复抗氧化防御系统并下调促炎信号通路。本研究观察结果为 Rg1 治疗急性肝损伤的临床应用提供了理论基础。